2
Total investments
0
Early stage
1
Mid stage
0
Late stage
2y
Years active
Portfolio
2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
First check investor
Jan 2025
Cultzyme is a deep-tech company developing innovative technologies for intelligent bioprocesses. Our full stack bioprocessing platform combines advanced hardware and AI to optimise biotech production autonomously.
Experience · 5 entries
All (5)
Investments (2)
Board (1)
2025
First check investor
Jan 2025
Cultzyme is a deep-tech company developing innovative technologies for intelligent bioprocesses. Our full stack bioprocessing platform combines advanced hardware and AI to optimise biotech production autonomously.
2024
First check investor - Board observer
Aug 2024
Next-generation recovery technologies for advanced industries.
Principal
Feb 2024
Fueling pioneers, turning bold science into planetary resilience. Nucleus is a first check deep-tech VC focused on Programmable Biology (Synbio & TechBio), Food Technology and Neo Industrials.
2023
Newton Scholar
Sep 2023
Newton Venture Program provides venture capital training and development for aspiring investors, practising investors, and others in the venture space. Our mission is to level the playing field for people from typically overlooked and underestimated backgrounds, ensuring that the next generation of investors represent the world we live in.
Newton Alumni span the globe with more than 500 people from all backgrounds going on to secure positions in VC firms, accelerate their careers in VC, and become disruptors of the status quo. As of the start of 2024, 46% identify as female or non-binary, and 49% identify as the global majority.
Newton is a joint venture between Phoenix Court and London Business School with founding partner, HSBC Innovation Banking. With our unique blend of faculty and practitioner teaching, we are training the investors of tomorrow to back the ventures of the future.
2015
Similar investors
Biotechnology investors in Germany
Investor lists
Lists that match Carolina's portfolio
- Biotechnology investors in Germany260 investors
- Manufacturing investors in Germany369 investors
- Startup investors in Germany2,001 investors






